New Polymorphisms in the PSA promoter in patients with prostate carcinoma

Schostak, Martin and Braun, C. and Krause, H. and Miller, K. and Kempkensteffen, C. and Hinz, S. and Strenziok, R. and Blana, A. and Schrader, M. (2007) New Polymorphisms in the PSA promoter in patients with prostate carcinoma. AKTUELLE UROLOGIE, 38 (6). pp. 465-472. ISSN 0001-7868,

Full text not available from this repository. (Request a copy)

Abstract

Introduction: PSA is still the most important parameter in the diagnosis and follow-up of prostate cancer. We searched for single nucleotide polymorphisms (SNP) in four different parts of the PSA promoter, which harbour binding sites for major transcriptional regulators using PCR-based combined SSCP and sequence analysis. Materials and Methods: Lymphocyte DNA samples from 279 prostate cancer patients and 55 age-matched controls were subjected to SSCP analysis after PCR amplification of four approximately 200-bp fragments selected to contain the known AREs I-III or the transcriptional start site, respectively. Conspicuous PCR fragments with variant SSCP patterns were subsequently cloned and sequenced. Computer-assisted comparison with published sequences of the promoter region was performed to reveal polymorphic sites. Results: In 66.6% of the carcinoma cases DNA displayed polymorphisms in ARE I-, whereas the benign cases showed this SNP only in 14.5 %. This difference was highly significant (p < 0.0001). In addition, we found novel SNPs with lower frequency at positions - 179, - 230, - 233 (ARE I) and - 356 (ARE II). Conclusion: The present study confirmed that the otherwise already described polymorphism in the position - 158 is highly significantly more frequent in prostate cancer patients than in the control group. There is no significant correlation to the clinical stage of the disease. Furthermore we described for the first time four rare, previously unknown polymorphisms.

Item Type: Article
Uncontrolled Keywords: ANTIGEN GENE PROMOTER; JAPANESE POPULATION; BREAST-CANCER; RISK; SUSCEPTIBILITY; ASSOCIATION; MUTATIONS; THERAPY; REGION; prostate cancer; polymorphisms; PSA
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Urologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 30 Nov 2020 08:22
Last Modified: 30 Nov 2020 08:22
URI: https://pred.uni-regensburg.de/id/eprint/31937

Actions (login required)

View Item View Item